Eltrombopag

Eltrombopag
Clinical data
Trade names	Promacta, Revolade, others
Other names	SB-497115-GR
AHFS/Drugs.com	Monograph
MedlinePlus	a609011
License data	US DailyMed: Eltrombopag_olamine;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	B02BX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	~52%
Protein binding	>99%
Metabolism	extensive liver (through CYP1A2 and CYP2C8)
Elimination half-life	21–35 hours
Excretion	feces (59%), urine (31%)
Identifiers
	IUPAC name 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid;
CAS Number	496775-61-2 ; as olamine: 496775-62-3;
PubChem CID	9846180; as olamine: 135449331;
DrugBank	DB06210 ; as olamine: DBSALT000063;
ChemSpider	21106301 ; as olamine: 28475107;
UNII	S56D65XJ9G; as olamine: 4U07F515LG;
KEGG	D03978;
ChEBI	CHEBI:85010;
ChEMBL	ChEMBL461101 ; as olamine: ChEMBL3989691;
CompTox Dashboard (EPA)	DTXSID5057753 ;
ECHA InfoCard	100.128.125
Chemical and physical data
Formula	C25H22N4O4
Molar mass	442.475 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O;
	InChI InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22- ; Key:XDXWLKQMMKQXPV-QYQHSDTDSA-N ;
	(what is this?) (verify)

Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is a thrombopoietin receptor agonist. It is taken by mouth.

Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals and is transferred to Novartis Pharmaceuticals.